TB-500 and Thymosin Beta-4: Why the Distinction Matters

TB-500 and full-length thymosin beta-4 are often discussed as if they were the same material. Published analytical work identified TB-500 as an acetylated seven-amino-acid fragment of thymosin beta-4. That distinction matters because evidence generated with the 43-amino-acid full-length protein cannot automatically be assigned to the shorter fragment.

At a glance

• Published analytical work identified TB-500 as Ac-LKKTETQ, a seven-amino-acid fragment.
• Full-length thymosin beta-4 contains 43 amino acids.
• Evidence for full-length thymosin beta-4 should not be transferred automatically to TB-500.
• Exact sequence and analytical identity are essential for interpreting research.
• TB-500 is listed by Health Canada among unauthorized injectable peptide products.

The nomenclature problem

Full-length human thymosin beta-4 is a 43-amino-acid peptide involved in actin regulation and cell migration. TB-500 has been used in the marketplace and in anti-doping literature to describe Ac-LKKTETQ, an acetylated fragment corresponding to residues 17-23 of thymosin beta-4.

Researchers should record the exact sequence, terminal modifications, molecular mass, and analytical identity of the material used. A label that says only “TB-500” is not enough to resolve whether a study or product concerns the fragment or full-length thymosin beta-4.

What analytical studies established

A 2012 analytical study used high-performance liquid chromatography and high-resolution mass spectrometry to identify the acetylated 17-23 fragment, Ac-LKKTETQ, in a TB-500 product. That work is important because it ties the commercial name to a specific short sequence rather than to the full 43-amino-acid molecule.

A 2024 study examined TB-500 and its metabolites with UHPLC-Orbitrap mass spectrometry. The authors reported that observed in-vitro wound-healing activity might relate to a metabolite rather than the parent fragment. This is an evolving mechanistic question, not proof of a clinical effect.

Why full-length thymosin beta-4 studies are separate

Preclinical wound-healing experiments and a small randomized Phase 2 venous-ulcer study investigated full-length synthetic thymosin beta-4. Those studies are relevant to the full-length molecule and its formulation, route, and study conditions.

They should not be cited as direct clinical evidence for Ac-LKKTETQ. Sequence length and molecular structure can change distribution, stability, binding, metabolism, and biological activity. Responsible interpretation keeps the evidence attached to the exact material tested.

Regulatory and quality context

Neither a mechanistic study nor a certificate reporting mass and purity establishes therapeutic safety or effectiveness. Identity testing, purity testing, sterility, endotoxin, stability, and toxicology answer different questions.

Health Canada includes TB-500 among unauthorized injectable peptide products in its 2026 public advisory. The agency warns that research-use-only wording does not make a product authorized or appropriate for human use.

Bottom line

The most important fact about TB-500 research is molecular identity. Ac-LKKTETQ and full-length thymosin beta-4 are related, but they are not interchangeable. Every scientific claim should identify which molecule was tested, in what model, by what route, and with what analytical confirmation.

Editorial standard: Sources were checked against the linked publication, trial registry, regulator, or sponsor page. Regulatory status and ongoing-trial information can change; this page is dated so readers can judge its currency.